Attila Bérces, Omixon CEO and founder, shared his recent Prezi formatted presentation that shows how next generation sequencing can serve as a diagnostic platform with a special focus on our software solution,Omixon Target.
We hope you will enjoy this:
The prestigious channel, GenomeWeb, published an article about “Software Vendors Cautiously Optimistic as Illumina Readies BaseSpace App Store for Market” and mentions Omixon. An excerpt from the article:
Omixon, for instance, is developing an HLA genotyping application for identifying disease associations using whole-genome or whole-exome data as well as from targeted sequencing data, Attila Bérces, the company’s CEO, told BioInform.
You can access the full article here (GenomeWeb subscription is needed). We are always happy when our work gets some attention from the international research communities.
We are grateful for the many researchers and genetists who attended our workshop on August 23, 2012 at Harvard Medical School. Omixon’s CEO, Attila Berces, initiated the workshop with a presentation of how targeted analysis differs from whole genome analysis.
The participants were able to test Omixon Target during the workshop, and witness its speed and accuracy first hand. Users also enjoyed working with the Omixon browser and being able to effectively visualize large amounts of data.
We have been highlighting the need for clinical applications in next-generation sequencing and affordable diagnostics for years and that was one of the reasons to organize a workshop at the Joseph B. Martin Conference Center, Harvard Medical School on the 23rd of August between 2 PM and 6PM where you can learn how to carry out the most precise mutation analysis for common diagnostic gene targets.
The workshop is, of course, free and all participants are provided with a free 6-month Omixon license. Finally, if you are interested in using Omixon Target, we offer a special 90% discount at the workshop.
You can find all the details here as well as the registration form. Please register soon as only a few seats left!
Budapest, Hungary – Today, 30 May 2012, Omixon – a genomic software company – announced the commercial release of Omixon Target, a next generation sequencing analysis software for targeted sequencing. Omixon built its new software Target with the vision of helping diagnostic labs to adapt next generation sequencing to replace and complement traditional capillary Sanger sequencing.
Target was designed “with diagnostics in mind” explains Tim Hague, CTO of Omixon. ”It was built for precision and it is undergoing various levels of validation. Target is the first NGS tool to introduce analysis quality control based on repeat analysis with mutated reference as well as with simulated short reads. This gives a realistic indication of false discovery rates for the given target.”
“We are using next-generation sequencing techniques to advance patient care at Almac and we know that accurate data and meaningful data interpretation are dependent upon employing the best analysis tools and techniques.” Said Gavin Oliver, bioinformatics team leader at Almac. “Omixon fully understand this requirement and are creating highly-tuned software solutions that will empower scientists by removing much of the uncertainty from these complex analyses.”
CEO of Omixon, Atiila Berces, adds, ” Targeted, or amplicon based sequencing is the method of choice for diagnosing several genetic disorders, screening for hereditary mutations of disease susceptibility genes or matching donors and recipients of organ transplantations. These targeted amplicons are increasingly sequenced by next generation sequencing. Each diagnostic target presents different analysis challenges from a computational standpoint. The sensitive detection of long insertions and deletions is crucial for several oncogenes, while the immune system related genes show orders of higher genetic diversity. Omixon Target uses profiles with parameters set up for the particular gene target, which guaranties the highest possible precision for diverse situation.”
